FrontPage is India's Stock Market Social Network
Join 50,000+ Traders and Investors
Find answers to all your questions on live JUBILANT message board: Is JUBILANT buy or sell? Should I buy JUBILANT shares? Why are JUBILANT shares falling? Should I invest in JUBILANT stock?
forum
JUBILANT Share Price Discussion
Jubilant Life Sciences Ltd.
NSE: JUBILANT | BSE: 530019 | ISIN: INE700A01033 | Sector: Pharmaceuticals and health care
N
Reputation: 4,625 • Jun 2 5:08 AM
Hold Jubilant Life Sciences; target of Rs 414: Prabhudas Lilladher
Prabhudas Lilladher recommended Hold rating on Jubilant Life Sciences with a target price of Rs 414 in its research report dated Jun 01, 2020.
Prabhudas Lilladher recommended Hold rating on Jubilant Life Sciences with a target price of Rs 414 in its research report dated Jun 01, 2020.
Moneycontrol
Like
Reply
NSE:JUBILANT price when posted: 487.45
Recent posts in JUBILANT
N
Reputation: 4,625 • Jul 31 1:53 AM
Remdesivir shortage to ease in August as existing suppliers boost capacity, new manufacturers enter
Around 8 lakh doses are expected to be available in the country in August as new manufacturers are getting ready to enter the market with their generic versions.
Around 8 lakh doses are expected to be available in the country in August as new manufacturers are getting ready to enter the market with their generic versions.
Moneycontrol
Like
Reply
N
Reputation: 4,625 • Jul 30 2:28 AM
Trade Spotlight: Dr Reddy’s, IndusInd Bank, Nestle, Maruti and Jubilant Life in focus
Indian market witnessed profit-taking at higher levels on Wednesday and the trend is likely to remain volatile on Thursday as well ahead of June F&O expiry.
Indian market witnessed profit-taking at higher levels on Wednesday and the trend is likely to remain volatile on Thursday as well ahead of June F&O expiry.
Moneycontrol
Like
Reply
N
Reputation: 4,625 • Jul 29 3:08 AM
Dr Reddy's expects to launch Remdesivir in August
On another antivral Favipiravir, which is prescribed for mild COVID-19 cases, Dr Reddy's said it will be going ahead with the product, despite Glenmark's clinical trial data hasn't been statistically significant.
On another antivral Favipiravir, which is prescribed for mild COVID-19 cases, Dr Reddy's said it will be going ahead with the product, despite Glenmark's clinical trial data hasn't been statistically significant.
Moneycontrol
Like
Reply